Advertisement

Molecular Imaging and Biology

, Volume 12, Issue 1, pp 78–84 | Cite as

Visualization of Somatostatin Receptors in Prostate Cancer and its Bone Metastases with Ga-68–DOTATOC PET/CT

  • Wolfgang Luboldt
  • Klaus Zöphel
  • Gerd Wunderlich
  • Andrij Abramyuk
  • Hans-Joachim Luboldt
  • Joerg Kotzerke
Research Article

Abstract

Purpose

To assess DOTATOC-affine somatostatin receptor expression in advanced prostate cancer and its bone metastases with regard to DOTATOC-mediated receptor therapies, using a Ga-68–DOTATOC PET/CT.

Procedures

Twenty consecutive patients with advanced prostate cancer underwent bone scintigraphy, followed by Ga-68–DOTATOC PET/CT within 3 weeks. Through side-by-side comparison with bone scintigraphy, the number of visible bone metastases on PET was determined. In addition, in cases of visible metastases, the maximum standard uptake value (SUVmax) of Ga-68–DOTATOC was measured in the metastases and in normal bone. In patients who did not undergo a prostatectomy (n = 12), the SUVmax was additionally measured in the prostate and in adjacent tissue. For focal lesions, the difference in SUVmax (ΔSUVmax) between the metastases and normal bone was calculated. For patients still having their prostate, a ΔSUVmax between the prostate and its adjacent tissue was calculated.

Results

Sixty four of 216 metastases (30%) were visible in 13 patients with focal metastases. Of six patients with diffuse metastases (superscan), one showed diffuse metastases, three showed a total of ten focal metastases, and two showed no correlate on PET. One patient with a neuroendocrine prostate cancer showed no correlate on PET. The maximum ΔSUVmax between metastases and normal bone was 4.9 (mean = 1.6 ± 0.9) and between the prostate and adjacent tissue 5.9 (mean = 2.8 ± 1.6).

Conclusions

In prostate cancer and its bone metastases, DOTATOC-affine somatostatin receptors (subtype 2 and 5) can be visualized with Ga-68–DOTATOC PET/CT. But their expression is so weak that other conjugates should be tested for receptor-mediated therapies which are better at addressing the prostate cancer-specific somatostatin receptor subtypes 1 and 4—or even other receptors.

Key words

Prostate cancer Somatostatin receptor Somatostatin receptor scintigraphy Somatostatin receptor radiation therapy Ga-68–DOTATOC PET/CT 

Abbreviations

DOTATOC

1,4,7,10-Tetraazacyclododecane-4,7,10-tricarboxy-methyl-1-yl-acety-d-Phe1-Try3-octreotide

PET/CT

Positron emission tomography/computed tomography

SUVmax

Maximum standard uptake value

SSTR

Somatostatin receptor

RRT

Receptor radiation therapy

CgA

Chromogranin A

References

  1. 1.
    Heidenreich A, Ohlmann CH (2005) Treatment options for hormone-refractory prostate cancer. Urologe A 44(11):1303–4, 1306–14Google Scholar
  2. 2.
    Schmid HP, Gregorin J, Altwein JE (2008) Growth hormone inhibitors in prostate cancer: a systematic analysis. Urol Int 81(1):17–22CrossRefPubMedGoogle Scholar
  3. 3.
    Kwekkeboom DJ, Kooij PP, Bakker WH, Macke HR, Krenning EP (1999) Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J Nucl Med 40(5):762–767PubMedGoogle Scholar
  4. 4.
    Cremonesi M, Ferrari M, Zoboli S et al (1999) Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: implications for internal radiotherapy with (90)Y-DOTATOC. Eur J Nucl Med 26(8):877–886CrossRefPubMedGoogle Scholar
  5. 5.
    Chinol M, Bodei L, Cremonesi M, Paganelli G (2002) Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group. Semin Nucl Med 32(2):141–147CrossRefPubMedGoogle Scholar
  6. 6.
    Forrer F, Waldherr C, Maecke HR, Mueller-Brand J (2006) Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 26(1B):703–707PubMedGoogle Scholar
  7. 7.
    Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP (2007) Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 21(1):111–129CrossRefPubMedGoogle Scholar
  8. 8.
    Zhernosekov KP, Filosofov DV, Baum RP et al (2007) Processing of generator-produced 68Ga for medical application. J Nucl Med 48(10):1741–1748 Epub 2007 Sep 14CrossRefPubMedGoogle Scholar
  9. 9.
    Heidenreich A, Aus G, Bolla M et al (2008) EAU guidelines on prostate cancer. Eur Urol 53(1):68–80CrossRefPubMedGoogle Scholar
  10. 10.
    Koutsilieris M, Mitsiades CS, Bogdanos J et al (2004) Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 10(13):4398–4405CrossRefPubMedGoogle Scholar
  11. 11.
    Mitsiades CS, Bogdanos J, Karamanolakis D, Milathianakis C, Dimopoulos T, Koutsilieris M (2006) Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res 26(5B):3693–3700PubMedGoogle Scholar
  12. 12.
    Reisine T, Bell GI (1995) Molecular biology of somatostatin receptors. Endocr Rev 16(4):427–442PubMedGoogle Scholar
  13. 13.
    Reubi JC, Waser B, Schaer JC, Laissue JA (2001) Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 28(7):836–846CrossRefPubMedGoogle Scholar
  14. 14.
    Hansson J, Bjartell A, Gadaleanu V, Dizeyi N, Abrahamsson PA (2002) Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate 53(1):50–59CrossRefPubMedGoogle Scholar
  15. 15.
    Sciarra A, Bosman C, Monti G et al (2004) Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma. J Urol 172(5 Pt 1):1775–1783CrossRefPubMedGoogle Scholar
  16. 16.
    Kosari F, Munz JM, Savci-Heijink CD et al (2008) Identification of prognostic biomarkers for prostate cancer. Clin Cancer Res 14(6):1734–1743CrossRefPubMedGoogle Scholar
  17. 17.
    Koutsilieris M, Tzanela M, Dimopoulos T (1999) Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. Prostate 38(4):313–316CrossRefPubMedGoogle Scholar
  18. 18.
    Koppan M, Nagy A, Schally AV, Arencibia JM, Plonowski A, Halmos G (1998) Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res 58(18):4132–4137PubMedGoogle Scholar
  19. 19.
    Krijnen JL, Janssen PJ, Ruizeveld de Winter JA, van Krimpen H, Schroder FH, van der Kwast TH (1993) Do neuroendocrine cells in human prostate cancer express androgen receptor. Histochemistry 100(5):393–398CrossRefPubMedGoogle Scholar
  20. 20.
    Di Sant'Agnese PA, Cockett AT (1994) The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J Urol 152(5 Pt 2):1927–1931PubMedGoogle Scholar
  21. 21.
    Abrahamsson PA (1999) Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 6(4):503–519CrossRefPubMedGoogle Scholar
  22. 22.
    Kwekkeboom DJ, Mueller-Brand J, Paganelli G et al (2005) Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 46(Suppl 1):62S–66SPubMedGoogle Scholar
  23. 23.
    Nilsson S, Reubi JC, Kalkner KM et al (1995) Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Cancer Res 55(23 Suppl):5805s–5810sPubMedGoogle Scholar
  24. 24.
    Hofmann M, Maecke H, Borner R et al (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28(12):1751–1757CrossRefPubMedGoogle Scholar
  25. 25.
    Gabriel M, Decristoforo C, Kendler D et al (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48(4):508–518CrossRefPubMedGoogle Scholar
  26. 26.
    Buchmann I, Henze M, Engelbrecht S et al (2007) Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 34(10):1617–1626CrossRefPubMedGoogle Scholar
  27. 27.
    Dizeyi N, Konrad L, Bjartell A et al (2002) Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 7(3):91–98CrossRefPubMedGoogle Scholar
  28. 28.
    Schuhmacher J, Zhang H, Doll J et al (2005) GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6–14) analog. J Nucl Med 46(4):691–699PubMedGoogle Scholar
  29. 29.
    Breeman WA, de Jong M, Erion JL et al (2002) Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 43(12):1650–1656PubMedGoogle Scholar
  30. 30.
    Miederer M, Seidl S, Buck A et al (2009) Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in (68)Ga–DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36(1):48–52CrossRefPubMedGoogle Scholar
  31. 31.
    Cimitan M, Buonadonna A, Cannizzaro R et al (2003) Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 14(7):1135–1141CrossRefPubMedGoogle Scholar
  32. 32.
    Namwongprom S, Wong FC, Tateishi U, Kim EE, Boonyaprapa S (2008) Correlation of chromogranin A levels and somatostatin receptor scintigraphy findings in the evaluation of metastases in carcinoid tumors. Ann Nucl Med 22(4):237–243CrossRefPubMedGoogle Scholar
  33. 33.
    Zophel K, Strumpf A, Wunderlich G, Oehme L, Eisenhofer G, Kotzerke J (2008) Cure of neuroendocrine carcinoma by peptide receptor radionuclide therapy. Clin Nucl Med 33(10):690–691CrossRefPubMedGoogle Scholar
  34. 34.
    Bodei L, Cremonesi M, Grana C et al (2004) Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 31(7):1038–1046CrossRefPubMedGoogle Scholar

Copyright information

© Academy of Molecular Imaging 2009

Authors and Affiliations

  • Wolfgang Luboldt
    • 1
  • Klaus Zöphel
    • 1
  • Gerd Wunderlich
    • 1
  • Andrij Abramyuk
    • 1
  • Hans-Joachim Luboldt
    • 2
  • Joerg Kotzerke
    • 1
  1. 1.Clinic and Policlinic of Nuclear MedicineUniversity Hospital DresdenDresdenGermany
  2. 2.Clinic and Policlinic of UrologyUniversity Hospital EssenEssenGermany

Personalised recommendations